Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept

To compare the changes in subfoveal choroidal thickness (CT) in eyes with neovascular age-related macular degeneration (nAMD) treated with intravitreal ranibizumab or aflibercept. In this retrospective case series, the medical records of 28 patients with nAMD treated with at least 3 consecutive mont...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of ocular pharmacology and therapeutics Ročník 31; číslo 6; s. 357
Hlavní autoři: Gharbiya, Magda, Cruciani, Filippo, Mariotti, Cesare, Grandinetti, Francesca, Marenco, Marco, Cacace, Vittorio
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.07.2015
Témata:
Aged
Aged, 80 and over
Angiogenesis Inhibitors - administration & dosage
Choroid - drug effects
Choroid - pathology
Endothelial Growth Factors - antagonists & inhibitors
Female
Follow-Up Studies
Fovea Centralis - drug effects
Humans
Intravitreal Injections
Macular Degeneration - drug therapy
Macular Degeneration - pathology
Male
Ranibizumab - administration & dosage
Receptors, Vascular Endothelial Growth Factor - administration & dosage
Recombinant Fusion Proteins - administration & dosage
Retrospective Studies
Tomography, Optical Coherence - methods
Visual Acuity - drug effects
Wet Macular Degeneration - drug therapy
ISSN:1557-7732, 1557-7732
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:To compare the changes in subfoveal choroidal thickness (CT) in eyes with neovascular age-related macular degeneration (nAMD) treated with intravitreal ranibizumab or aflibercept. In this retrospective case series, the medical records of 28 patients with nAMD treated with at least 3 consecutive monthly injections of ranibizumab (0.5 mg/0.05 mL) or aflibercept (2 mg/0.05 mL) between December 2013 and June 2014 and who were followed up for at least 3 months were reviewed. Subfoveal choroidal thickness was measured using enhanced depth imaging optical coherence tomography. Choroidal thickness decreased over time in the aflibercept group, but was unchanged throughout the study in the ranibizumab group. At each time point, the decrease was significantly greater in aflibercept-treated eyes compared with ranibizumab-treated eyes (P<0.05). No significant change in best-corrected visual acuity (BCVA) was seen in either group during follow-up. There was no correlation between change in choroidal thickness and age, sex, duration of previous antivascular endothelial growth factor treatment, number of previous injections, spherical equivalent, baseline choroidal thickness, and the BCVA outcome in either group. Subfoveal choroidal thickness appeared to decrease significantly in eyes with nAMD during 3 months of aflibercept treatment. No corresponding decrease in choroidal thickness occurred in ranibizumab-treated eyes.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1557-7732
1557-7732
DOI:10.1089/jop.2014.0160